Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trialNalinie Joharatnam‐Hogan, R. Steele, Stephen Falk et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 64
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancerRohini Sharma, Hani Gabra, Janet Graham et al.|BMC Cancer|2011Cited by 10
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)Khurum Khan, T.R. Jeffry Evans, Uma Mukherjee et al.|Molecular Cancer Therapeutics|2023Cited by 1